| mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.15 |
5e-06 |
| mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.13 |
7e-06 |
| mRNA |
Doxorubicin |
CTRPv2 |
pan-cancer |
AAC |
-0.12 |
4e-05 |
| mRNA |
CX-5461 |
GDSC1000 |
pan-cancer |
AAC |
-0.13 |
5e-05 |
| mRNA |
BRD-K88742110 |
CTRPv2 |
pan-cancer |
AAC |
-0.13 |
0.0002 |
| mRNA |
BRD-K17060750 |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
0.0003 |
| mRNA |
Talazoparib |
GDSC1000 |
pan-cancer |
AAC |
-0.12 |
0.0005 |
| mRNA |
decitabine:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.11 |
0.0005 |
| mRNA |
CAL-101 |
GDSC1000 |
pan-cancer |
AAC |
-0.1 |
0.0008 |
| mRNA |
GSK1070916 |
GDSC1000 |
pan-cancer |
AAC |
-0.1 |
0.0009 |